Exelixis Email Format

Biotechnology Research
1,001-2,500 employees
Alameda, CA, USA

Exelixis is a biotechnology company focused on discovering, developing, and commercializing innovative cancer treatments to improve outcomes for patients worldwide.

Find contacts at Exelixis

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

firstinitiallast@exelixis.com

Company Overview

Industry
Biotechnology Research
Founded
1994
Headquarters
Alameda, CA, USA
Revenue
$1B-$2.5B
FUNDING Stage
Public
Key Executives
Michael M. Morrissey, Ph.D. (President and Chief Executive Officer), Christopher J. Senner (Executive Vice President and Chief Financial Officer), P.J. Haley (Executive Vice President, Commercial)

Tech Stack

Salesforce

CRM

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of Exelixis?

Exelixis uses the firstinitiallast@exelixis.com format on exelixis.com, so Jane Smith would be jsmith@exelixis.com.

What approved cancer medicines does Exelixis currently market?

Exelixis markets two FDA-approved cabozantinib-based medicines: CABOMETYX, used to treat renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ, approved for progressive medullary thyroid cancer. Both are sold under the Exelixis commercial organization led by EVP P.J. Haley.

How many employees does Exelixis have?

Exelixis has approximately 1,536 employees and is headquartered in Alameda, California.

What is zanzalintinib and how does it fit into the Exelixis pipeline?

Zanzalintinib (XL092) is Exelixis's next-generation TKI targeting MET, VEGFR, AXL, and MER, and is currently being studied in multiple Phase 3 trials spanning colorectal cancer, renal cell carcinoma, and neuroendocrine tumors, making it the lead internal compound in the Exelixis pipeline.

Who leads Exelixis as its chief executive?

Michael M. Morrissey, Ph.D. serves as President and Chief Executive Officer of Exelixis and has guided the company through the commercial growth of CABOMETYX and the expansion of its oncology pipeline.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles